KERRY TAVEIRA: Open Payments
NPI 1447222856 · SWANSEA, MA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$910 in 64 payments from 13 companies in 2025. Trend: 2023 $999 · 2024 $791 · 2025 $910
Food & beverage: $910
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 27 | $167 |
| Alkermes, Inc. | 9 | $154 |
| Neurocrine BioSciences, Inc. | 5 | $103 |
| Axsome Therapeutics, Inc. | 5 | $102 |
| ABBVIE INC. | 4 | $80 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $67 |
| Janssen Pharmaceuticals, Inc | 3 | $65 |
| Vanda Pharmaceuticals Inc. | 2 | $53 |
| Supernus Pharmaceuticals, Inc. | 2 | $46 |
| Collegium Pharmaceutical, Inc. | 1 | $21 |
Products named: ARISTADA, REXULTI, INGREZZA, Auvelity, VRAYLAR, CAPLYTA, FANAPT, Qelbree.
Industry payments across MA — which companies pay providers there.
